UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (27162) 27162
Book Chapter (680) 680
Dissertation (504) 504
Conference Proceeding (174) 174
Publication (151) 151
Book / eBook (46) 46
Poster (18) 18
Government Document (12) 12
Web Resource (12) 12
Magazine Article (10) 10
Journal / eJournal (7) 7
Paper (5) 5
Report (4) 4
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (18760) 18760
life sciences & biomedicine (18185) 18185
humans (16268) 16268
prognosis (13712) 13712
female (12985) 12985
middle aged (11074) 11074
male (10840) 10840
prognostic factors (10562) 10562
oncology (9737) 9737
aged (9644) 9644
adult (8773) 8773
prognostic factor (5692) 5692
retrospective studies (4884) 4884
aged, 80 and over (4878) 4878
cancer (3656) 3656
surgery (3512) 3512
neoplasm staging (3470) 3470
survival analysis (3367) 3367
treatment outcome (3327) 3327
analysis (3176) 3176
survival rate (3134) 3134
survival (3117) 3117
risk factors (3093) 3093
multivariate analysis (2854) 2854
medical prognosis (2714) 2714
disease-free survival (2431) 2431
adolescent (2413) 2413
follow-up studies (2409) 2409
chemotherapy (2356) 2356
care and treatment (2289) 2289
medicine & public health (2263) 2263
breast cancer (2253) 2253
metastasis (2251) 2251
immunohistochemistry (1998) 1998
research (1942) 1942
proportional hazards models (1857) 1857
hematology (1808) 1808
patients (1784) 1784
kaplan-meier estimate (1757) 1757
tumors (1742) 1742
young adult (1737) 1737
predictive value of tests (1490) 1490
mortality (1405) 1405
biomarkers (1344) 1344
prognostic (1344) 1344
time factors (1332) 1332
child (1307) 1307
health aspects (1282) 1282
patient outcomes (1278) 1278
radiotherapy (1277) 1277
prognostic marker (1256) 1256
lymphatic metastasis (1254) 1254
prospective studies (1247) 1247
antineoplastic combined chemotherapy protocols - therapeutic use (1236) 1236
gene expression (1219) 1219
pathology (1216) 1216
medical research (1191) 1191
breast neoplasms - pathology (1180) 1180
colorectal cancer (1108) 1108
gastroenterology & hepatology (1108) 1108
prognostic markers (1103) 1103
neurosciences & neurology (1082) 1082
combined modality therapy (1066) 1066
development and progression (1024) 1024
abridged index medicus (1003) 1003
clinical neurology (992) 992
cohort studies (987) 987
hematology, oncology and palliative medicine (967) 967
age factors (956) 956
disease progression (946) 946
biomarkers, tumor - metabolism (940) 940
medicine, experimental (934) 934
studies (900) 900
medicine (888) 888
original (875) 875
diagnosis (863) 863
genetic aspects (850) 850
child, preschool (845) 845
neoplasm invasiveness (837) 837
recurrence (830) 830
general & internal medicine (809) 809
gene expression regulation, neoplastic (797) 797
metastases (791) 791
biomarkers, tumor - genetics (780) 780
regression analysis (780) 780
prognostic value (770) 770
radiology, nuclear medicine & medical imaging (769) 769
lung cancer (768) 768
biomarkers, tumor - analysis (765) 765
cancer therapies (758) 758
cell biology (753) 753
risk assessment (753) 753
proteins (747) 747
obstetrics & gynecology (732) 732
neoplasm metastasis (723) 723
cancer research (709) 709
original article (706) 706
radiation therapy (700) 700
medicine, research & experimental (689) 689
oncology, experimental (675) 675
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (26) 26
Collection Dvlpm't (Acquisitions) - Closed Orders (6) 6
Collection Dvlpm't (Acquisitions) - Vendor file (6) 6
UofT at Mississauga - Stacks (5) 5
Online Resources - Online (3) 3
Providence Healthcare - Stacks (3) 3
Robarts - Stacks (3) 3
St. Michael's College (John M. Kelly) - 2nd Floor (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
Mathematical Sciences - Missing (1) 1
OISE - Stacks (1) 1
Toronto East General Hospital - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
Victoria University Emmanuel College - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (26400) 26400
Portuguese (642) 642
Japanese (551) 551
French (441) 441
Spanish (421) 421
Korean (298) 298
German (168) 168
Russian (148) 148
Polish (146) 146
Czech (74) 74
Italian (73) 73
Chinese (58) 58
Hungarian (24) 24
Turkish (24) 24
Slovak (18) 18
Norwegian (11) 11
Dutch (10) 10
Lithuanian (9) 9
Persian (9) 9
Swedish (7) 7
Serbian (6) 6
Breton (5) 5
Croatian (5) 5
Ukrainian (4) 4
Arabic (3) 3
Slovenian (3) 3
Catalan (2) 2
Danish (2) 2
Icelandic (2) 2
Azerbaijani (1) 1
Hebrew (1) 1
Indonesian (1) 1
Latvian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2009, ISBN 0199559120, xix, 295 p., [8] p. of plates
One of the most widespread words in medicine is the placebo and placebo effect, although it is not always clear what it means exactly. Recent progress in... 
Placebos | Suggestion | Placebos (Medicine) | Treatment Outcome | Placebo Effect | therapeutic use | Molecular and Cellular Systems | Learning | Biological mechanisms | Disease | Nocebo | Therapeutic intervention | Placebo | Psychosocial context | Conditioning | Expectation
Book
British journal of haematology, ISSN 0007-1048, 08/2011, Volume 154, Issue 3, pp. 325 - 336
Summary Overexpression of the transcription factor interferon regulatory factor‐4 (IRF4), which is common in multiple myeloma... 
multiple myeloma | lenalidomide | prognostic markers | immunomodulatory | interferon regulatory factor‐4 | Interferon regulatory factor-4 | Prognostic markers | Immunomodulatory | Lenalidomide | Multiple myeloma | Life Sciences & Biomedicine | Hematology | Science & Technology | Cell Proliferation | Prognosis | Humans | Interferon Regulatory Factors - antagonists & inhibitors | Middle Aged | Antineoplastic Agents - therapeutic use | Genes, myc | Thalidomide - pharmacology | Gene Knockdown Techniques | Dose-Response Relationship, Drug | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Reverse Transcriptase Polymerase Chain Reaction - methods | Interferon Regulatory Factors - biosynthesis | Aged, 80 and over | Adult | Antineoplastic Agents - pharmacology | Retrospective Studies | Gene Expression Regulation, Neoplastic - drug effects | Tumor Cells, Cultured | Neoplasm Proteins - genetics | Neoplasm Proteins - biosynthesis | Interferon Regulatory Factors - genetics | Gene Expression Profiling - methods | Treatment Outcome | Down-Regulation - drug effects | Multiple Myeloma - metabolism | Multiple Myeloma - pathology | Aged | Biomarkers, Tumor - genetics | Thalidomide - therapeutic use | Biomarkers, Tumor - biosynthesis | Medical colleges | Analysis | Interferon | Angiogenesis inhibitors | Biological response modifiers | Index Medicus | Cell proliferation | Drugs | Transcription factors | Cell survival | Immunomodulation | biomarkers | Data processing | Myc protein | Cell death | Interferon regulatory factor 4 | Cell cycle | Bone marrow
Journal Article
Cancer, ISSN 0008-543X, 08/2007, Volume 110, Issue 3, pp. 543 - 550
BACKGROUND. Therapy targeted against the vascular endothelial growth factor (VEGF) pathway is a standard of care for patients with metastatic renal cell carcinoma... 
prognostic factors | prognostic model | advanced renal cell carcinoma | vascular endothelial growth factor | angiogenesis | Angiogenesis | Prognostic model | Vascular endothelial growth factor | Advanced renal cell carcinoma | Prognostic factors | Life Sciences & Biomedicine | Oncology | Science & Technology | Niacinamide - analogs & derivatives | Prognosis | Prospective Studies | Humans | Middle Aged | Neovascularization, Pathologic | Imidazoles - administration & dosage | Male | Kidney Neoplasms - metabolism | Phenylurea Compounds | Vascular Endothelial Growth Factor A - metabolism | Benzenesulfonates - administration & dosage | Indazoles - administration & dosage | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Indoles - administration & dosage | Bevacizumab | Antibodies, Monoclonal, Humanized | Clinical Trials, Phase III as Topic | Pyrroles - administration & dosage | Female | Carcinoma, Renal Cell - drug therapy | Pyridines - administration & dosage | Carcinoma, Renal Cell - pathology | Survival Rate | Vascular Endothelial Growth Factor A - immunology | Randomized Controlled Trials as Topic | Carcinoma, Renal Cell - metabolism | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Kidney Neoplasms - pathology | Kidney Neoplasms - drug therapy | Clinical Trials, Phase II as Topic | Patient outcomes | Physiological aspects | Carcinoma, Renal cell | Diagnosis | Research | Metastasis | Neovascularization | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Clinical cancer research, ISSN 1557-3265, 11/2018, Volume 24, Issue 21, pp. 5422 - 5432
.... Bioinformatics analyses of splicing factors potentially linked to bladder cancer progression identified the heterogeneous nuclear ribonucleoprotein I (i.e., PTBP1) as candidate... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Index Medicus
Journal Article
Journal Article
Clinical cancer research, ISSN 1557-3265, 04/2018, Volume 24, Issue 20, pp. 4960 - 4967
...) with other baseline clinical factors and outcomes in pembrolizumab-treated patients with advanced melanoma in KEYNOTE-001 (NCT01295827... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Index Medicus | anti–PD-1 | Immunotherapy | prognostic factors
Journal Article